Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- Qol Opens Dispensing Pharmacy at Major Electronics Retail Store
August 15, 2011
- Nichi-Iko to Strengthen Relationships with Wholesalers
August 15, 2011
- NCVC to Expand Infrastructure for 1st-in-human Studies for Medical Devices
August 15, 2011
- FIRM Starts Activities Creating 3 WGs
August 15, 2011
- Daiichi Sankyo to Expand Hybrid Business Model in Mexico
August 15, 2011
- Combination Drugs Are Part of Innovation: Prof. Kaku of Kawasaki Medical School
August 15, 2011
- Statistics
August 15, 2011
- DSP Not Planning Full-scale Entry into Generic Business: President Tada
August 15, 2011
- Korosho Forecasts 92,000 Patients Admitted for Dementia in 2026
August 15, 2011
- Korosho's Study Group Proposes Qualifications for GMP Inspectors
August 15, 2011
- Fuji Pharma: Sales Up 7% Driven by Hormonal Drugs
August 15, 2011
- M3 Survey of Doctors Finds Differences in Ways Companies Detail AD Treatments
August 15, 2011
- Fee-for-Service Reimbursement to Be Permitted for Wider Range of High-priced Drugs
August 15, 2011
- SRUVEY
August 15, 2011
- Female Life Expectancy Down Slightly in 2010; First Decline in 5 Years
August 15, 2011
- PMDA to Initiate Clinical Trial Consultation for Orphan Drugs
August 15, 2011
- Takeda Discontinues Development of Anti-obesity Drug in US
August 15, 2011
- Growth in Diabetes Drug Market Driven by DPP-4 Inhibitors in 2010: Yano Research
August 15, 2011
- JPA President Kodama to Explain about Leaked Copy of His Appeal at General Assembly
August 15, 2011
- NCCHD Creates Pediatric Clinical Trial Network of 27 Facilities
August 15, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…